<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE mutation PUBLIC "mutation" "cancer-mutation.dtd">
<mutation>
  <publication>
    <authorlist>Denisova E, Heidenreich B, Nagore E, Rachakonda PS, Hosen I, Akrap I, Traves V, García-Casado Z, López-Guerrero JA, Requena C, Sanmartin O, Serra-Guillén C, Llombart B, Guillén C, Ferrando J, Gimeno E, Nordheim A, Hemminki K, Kumar R</authorlist>
    <title>Frequent DPH3 promoter mutations in skin cancers</title>
    <journal>Oncotarget</journal>
    <year>2015</year>
    <volume>[Epub ahead of print]</volume>
    <pages>null</pages>
    <pmid>26416425</pmid>
  </publication>
  <variantlist>
    <variant genotype="heterozygous" class="promoter">
      <build>37</build>
      <chromosome>3</chromosome>
      <pos>16306504</pos>
      <ref>C</ref>
      <alt>T</alt>
      <snippet>TAGC[C/T]CTTCCGG</snippet>
      <regulator>DPH3 promoter</regulator>
      <pathomechanism>promoter|unknown</pathomechanism>
      <validation>
        <frequency m="3" n="31"/>
      </validation>
    </variant>
  </variantlist>
  <disease>
    <name>Skin Squamous Cell Carcinoma</name>
    <database>NCI</database>
    <id>C4819</id>
  </disease>
  <metadata>The authors performed exome sequencing of 21 melanomas, and report frequent somatic mutations in skin cancers in a bidirectional promoter of diphthamide biosynthesis 3 (DPH3) and oxidoreductase NAD-binding domain containing 1 (OXNAD1) genes. The UV-signature mutations occurred at sites adjacent and within a binding motif for E-twenty six/ternary complex factors (Ets/TCF), at -8 and -9 bp from DPH3 transcription start site. Follow up screening of 586 different skin lesions showed that the DPH3 promoter mutations were present in melanocytic nevi (2/114; 2%), melanoma (30/304; 10%), basal cell carcinoma of skin (BCC; 57/137; 42%) and squamous cell carcinoma of skin (SCC; 12/31; 39%). Reporter assays carried out in one melanoma cell line for DPH3 and OXNAD1 orientations showed statistically significant increased promoter activity due to -8/-9CC > TT tandem mutations; although, no effect of the mutations on DPH3 and OXNAD1 transcription in tumors was observed. Here, a variant at hg19 coordinate chr3:16,306,504 that is 8 bp upstream of DPH3 RefSeq transcription start site (TSS), hence named -8C>T, is described.</metadata>
  <targetgene>
    <entrezid>285381</entrezid>
    <genesymbol>DPH3</genesymbol>
  </targetgene>
  <biocurator>HPO:probinson</biocurator>
  <datecreated>1447492789014</datecreated>
  <datemodified>1447492789014</datemodified>
</mutation>
